Healios Acquires Bankrupt Athersys, Expands Cell Therapy R&D Programs

 
• By Lisa Takagi

Tokyo-based Healios will lead the global clinical studies for Athersys’ cell therapy MultiStem for ARDS and start US Phase II trials for trauma following their long-term collaboration.

Healios will announce further strategy on acquired assets from Athersys once its policy is finalized, the firm says.
Healios set to unveil strategy for acquired Athersys assets • Source: Shutterstock

More from Deals

More from Business